Good MorningEquity markets tried to rebound from Wednesday's unexpected selloff on Thursday but failed to regain the prior days' losses. The S&P gained 1% for the day but closed well off the highs for the week. The weekly pattern suggests a rising level of fear ahead of the PCE report, due out Friday. The PCE report is expected to confirm slowing inflation but at an insufficient pace to allow the FOMC to cut interest rates soon.
The S&P 500 price action shows resistance below the all-time high, a critical hurdle for the market. Given the proper catalyst, resistance at this level could lead to range-bound trading or a sharp correction. That catalyst could come soon, given the risk of inflation accelerating. Oil markets are already stabilizing after their correction, and ocean-going freight rates are through the roof on geopolitical concerns centered on the Red Sea. Featured: Forget NVDA. Buy this A.I. stock instead (Chaikin Analytics) 
|
Markets | | |
Move over FAANG, there’s a new and improved basket of stocks leading the way: The ‘Magnificent Seven.’
Earlier this year, Bank of America's Michael Hartnett dubbed a group of top stocks the "Magnificent Seven". These global leading companies focus on tech trends like AI, cloud c... Read the Full Story |
|
From Our PartnersThe internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. | | | | Here's the #1 stock to buy. |
|
Markets | | |
Santa Claus rally or not, the analysts are upping their targets on some high-quality tech names that stand to rally strongly in 2024.
Salesforce.com Inc. (NYSE: CRM), Zscaler Inc. (NASDAQ: ZS) and Workday Inc. (NASDAQ: WDAY) are all supported by secular trends that shoul... Read the Full Story |
|
Markets | | |
A Roth IRA is a tax-advantaged individual retirement account that you can use to contribute after-tax dollars. How many Roth IRAs can I have?
If you follow the rules, Roth IRAs have the advantage of tax-free growth and withdrawals.
You can have as many Roth IRAs as you desire, but the annual c... Read the Full Story |
|
From Our Partners=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>> | | | | Get the name of the stock here |
|
Markets | | | Wall Street capped its eighth straight winning week with a quiet finish Friday, following reports showing inflation on the way down and the economy potentially on the way up.The S&P 500 rose 0.2% to sit less than 1% below its record set nearly two years ago. The Dow Jones Industrial Average sli... Read the Full Story |
|
Markets | | | Asian markets were steady in holiday-thinned trading on Tuesday, with some markets in the region closed for holidays. U.S. futures and oil prices edged higher. Shanghai’s benchmark led losses in Asia on heavy selling of technology and computer chip-related shares as worries revived over trade tensio... Read the Full Story |
|
From Our PartnersHi there, it's Tom Busby, founder of the Diversified Trading Institute and while we know that it's not possible to trade 24 hours a day, it is possible to learn how to profit like you do! With my new guide, the "Little Black Book", you can discover how to leverage every market to help you earn more, even when the trading day is done. | | Click here for your free copy now! |
|
Markets | | |
Investing wisely for retirement is crucial, especially as Social Security's reliability wanes amidst a growing national deficit. Relying solely on government subsidies could be a precarious gamble. Supplementing fixed income sources becomes essential; the earlier you start, the bigger your nest eg... Read the Full Story |
|
Markets | | |
The big swoosh is set to look a little deflated heading into 2024 after Nike Inc (NYSE: NKE) reported its fiscal Q2 earnings last night. Shares had been rallying since the end of September, gaining close to 40% through yesterday's close, so expectations were clearly high f... Read the Full Story |
|
Markets | | | The Cuban government said Friday it will have to either increase prices for fuel and electricity, or reduce rations for basic supplies. President Miguel Díaz-Canel said such difficult measures were needed for difficult times, after the minister of the economy said Cuba’s economy contracted between 1... Read the Full Story |
|
Markets | | | The Czech Republic’s central bank cut its key interest rate Thursday hoping to give the country's struggling economy a boost.The cut by a quarter of a percentage point brought the interest rate down to 6.75%. It was the first time the bank cut the rate since June 22 last year.Last year the bank rais... Read the Full Story |
|
Markets | | | The ripple effects of the war in Gaza are likely to knock Lebanon’s fragile economy, which had begun making a tepid recovery after years of crisis, back into recession, the World Bank said in a report released Thursday.Before the outbreak of the ongoing Israel-Hamas war on Oct. 7, the World Bank had... Read the Full Story |
|
Monday's Early Bird Stock Of The Day argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. | | View Today's Stock Pick |
|
